Treatment to target in patients with inflammatory bowel disease. What is the evidence?

References

• Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15(3):315.
   PubMedGoogle Scholar
• Fasci Spurio F, Aratari A, Margagnoni G, et al. Early treatment in Crohn’s disease: do we have enough evidence to reverse the therapeutic pyramid? J Gastrointestin Liver Dis. 2012;21(1):67–73.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology. 1999;116(5):1029–1034.
   PubMed Web of Science ®Google Scholar
• Magro F, Lopes SI, Lopes J, et al. Histological outcomes and predictive value of faecal markers in moderately to severely active ulcerative colitis patients receiving infliximab. J Crohns Colitis. 2016;10(12):1407–1416.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008;135(5):1493–1499.
   PubMed Web of Science ®Google Scholar
• Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412–422.
   PubMed Web of Science ®Google Scholar
• Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386(10006):1825–1834.
   PubMed Web of Science ®Google Scholar
• Papay P, Ignjatovic A, Karmiris K, et al. Optimising monitoring in the management of Crohn’s disease: a physician’s perspective. J Crohns Colitis. 2013;7(8):653–669.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Pouillon L, Peyrin-Biroulet L. It is time to revise the STRIDE guidelines determining therapeutic goals for treat-to-target in inflammatory bowel disease. J Crohns Colitis. 2018;12(4):509–509.
   PubMed Web of Science ®Google Scholar
• Panes J, Jairath V, Levesque BG. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology. 2017;152(2):362–373.e3.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Cochrane handbook – risk of bias assessment. [cited 2018 Dec 5]. Available from: http://handbook-5-1.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm
   Google Scholar
• Hinneburg I. ROBINS-1: a tool for asssessing risk of bias in non-randomised studies of interventions. Med Monatsschr Pharm. 2017;40(4):175–177.
   PubMedGoogle Scholar
• Mensink PB, Aktas H, Zelinkova Z, et al. Impact of double-balloon enteroscopy findings on the management of Crohn’s disease. Scand J Gastroenterol. 2010;45(4):483–489.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Yamamura T, Maeda K, et al. Validity of capsule endoscopy in monitoring therapeutic interventions in patients with Crohn’s disease. J Clin Med. 2018;7(10):311.
   Web of Science ®Google Scholar
• Oliva S, Aloi M, Viola F, et al. A treat to target strategy using pan-enteric capsule endoscopy in pediatric patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2019;17:2060–2067.
   PubMed Web of Science ®Google Scholar
• Kim DH, Park SJ, Park JJ, et al. Effect of follow-up endoscopy on the outcomes of patients with inflammatory bowel disease. Dig Dis Sci. 2014;59(10):2514–2522.
   PubMed Web of Science ®Google Scholar
• Bouguen G, Levesque BG, Pola S, et al. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(6):978–985.
   PubMed Web of Science ®Google Scholar
• Bouguen G, Levesque BG, Pola S, et al. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014;20(2):231–239.
   PubMed Web of Science ®Google Scholar
• De Cruz P, Kamm MA, Hamilton AL, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;385(9976):1406–1417.
   PubMed Web of Science ®Google Scholar
• Ferrante M, Papamichael K, Duricova D, et al. Systematic versus endoscopy-driven treatment with azathioprine to prevent postoperative ileal Crohn’s disease recurrence. J Crohns Colitis. 2015;9(8):617–624.
   PubMed Web of Science ®Google Scholar
• Guo Z, Cai X, Liu R, et al. Immediate prophylactic vs endoscopic or symptomatic-driven azathioprine treatment to prevent surgical recurrence after intestinal resection for Crohn’s disease. Colorectal Dis. 2018;20(9):O267–O276.
   PubMed Web of Science ®Google Scholar
• De Cruz P, Bernardi MP, Kamm MA, et al. Postoperative recurrence of Crohn’s disease: impact of endoscopic monitoring and treatment step-up. Colorectal Dis. 2013;15(2):187–197.
   PubMed Web of Science ®Google Scholar
• Boucher AL, Pereira B, Decousus S, et al. Endoscopy-based management decreases the risk of postoperative recurrences in Crohn’s disease. World J Gastroenterol. 2016;22(21):5068–5078.
   PubMed Web of Science ®Google Scholar
• Bordeianou L, Stein SL, Ho VP, et al. Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn’s disease? Surgery. 2011;149(1):72–78.
   PubMed Web of Science ®Google Scholar
• Baudry C, Pariente B, Lourenco N, et al. Tailored treatment according to early post-surgery colonoscopy reduces clinical recurrence in Crohn’s disease: a retrospective study. Dig Liver Dis. 2014;46(10):887–892.
   PubMedGoogle Scholar
• Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–2789.
   PubMed Web of Science ®Google Scholar
• Lasson A, Ohman L, Stotzer PO, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: a prospective, randomized, controlled study. United European Gastroenterol J. 2015;3(1):72–79.
   PubMed Web of Science ®Google Scholar
• Spradlin NM, Wise PE, Herline AJ, et al. A randomized prospective trial of endoscopic ultrasound to guide combination medical and surgical treatment for Crohn’s perianal fistulas. Am J Gastroenterol. 2008;103(10):2527–2535.
   PubMed Web of Science ®Google Scholar
• Wiese DM, Beaulieu D, Slaughter JC, et al. Use of endoscopic ultrasound to guide adalimumab treatment in perianal Crohn’s disease results in faster fistula healing. Inflamm Bowel Dis. 2015;21(7):1594–1599.
   PubMed Web of Science ®Google Scholar
• Rosen MJ, Moulton DE, Koyama T, et al. Endoscopic ultrasound to guide the combined medical and surgical management of pediatric perianal Crohn’s disease. Inflamm Bowel Dis. 2010;16(3):461–468.
   PubMed Web of Science ®Google Scholar
• Guidi L, Ratto C, Semeraro S, et al. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn’s disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol. 2008;12(2):111–117.
   PubMed Web of Science ®Google Scholar
• Deepak P, Fletcher JG, Fidler JL, et al. Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn’s disease. Am J Gastroenterol. 2016;111(7):997–1006.
   PubMed Web of Science ®Google Scholar
• Chambaz M, Verdalle-Cazes M, Desprez C, et al. Deep remission on magnetic resonance imaging impacts outcomes of perianal fistulizing Crohn’s disease. Dig Liver Dis. 2019;51(3):358–363.
   PubMedGoogle Scholar
• D’Haens G, Vermeire S, Lambrecht G, et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease. Gastroenterology. 2018;154(5):1343–1351.e1.
   PubMed Web of Science ®Google Scholar
• Bryant RV, Winer S, Spl T, et al. Systematic review: histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 2014;8(12):1582–1597.
   PubMed Web of Science ®Google Scholar
• Mosli MH, Parker CE, Nelson SA, et al. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2017;(5):CD011256.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel JF, Bossuyt P, et al. Long-term cost-effectiveness of tight control for Crohn’s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial. J Crohns Colitis. 2018;12(Supplement 1):S74–S75.
   Google Scholar
• Panaccione R, Colombel JF, Bossuyt P, et al. Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. J Crohns Colitis. 2018;12(Supplement 1):S78–S79.
   Google Scholar
• Wright EK, Kamm MA, De Cruz P, et al. Structured post-operative treatment and monitoring to prevent Crohn’s disease recurrence is cost effective. Results from the POCER study. J Gastroenterol Hepatol. 2015;30(S3):145.
   Web of Science ®Google Scholar
• Ng SC, Arslan Lied G, Arebi N, et al. Clinical and surgical recurrence of Crohn’s disease after ileocolonic resection in a specialist unit. Eur J Gastroenterol Hepatol. 2009;21(5):551–557.
   PubMed Web of Science ®Google Scholar
• Chardavoyne R, Flint GW, Pollack S, et al. Factors affecting recurrence following resection for Crohn’s disease. Dis Colon Rectum. 1986;29(8):495–502.
   PubMed Web of Science ®Google Scholar
• Spinelli A, Sacchi M, Fiorino G, et al. Risk of postoperative recurrence and postoperative management of Crohn’s disease. World J Gastroenterol. 2011;17(27):3213–3219.
   PubMed Web of Science ®Google Scholar
• Buisson A, Gonzalez F, Poullenot F, et al. Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(8):1425–1433.
   PubMed Web of Science ®Google Scholar
• Ricciuto A, Dhaliwal J, Walters TD, et al. Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis. J Crohns Colitis. 2018;12(11):1302–1315.
   PubMed Web of Science ®Google Scholar
• Feagan B. Care Path for the Management of Ulcerative Colitis (CONSTRUCT). Clinicaltrials.gov. 2014 [cited 2016 May 13]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01882426?term=treat+to+target&cond=Inflammatory+Bowel+Diseases+OR+colitis+ulcerosa+OR+crohn%27s+disease&draw=23
   Google Scholar
• Janssen-Cilag Ltd. Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn’s Disease Patients Treated with Ustekinumab (STARDUST). Clinicaltrials.gov. 2017 [cited 2018 Nov 28]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03107793?term=treat+to+target&cond=Inflammatory+Bowel+Diseases+OR+colitis+ulcerosa+OR+crohn%27s+disease&rank=2&view=record
   Google Scholar
• Feagan B. Enhanced Algorithm for Crohn’s Treatment Incorporating Early Combination Therapy (REACT2). Clinicaltrials.gov. 2012 [cited 2018 Oct 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01698307?term=NCT01698307&rank=1
   Google Scholar
• Hoff DAL. The CalproSmartNOR Study – a new clinical tool for monitoring patients with inflammatory bowel disease. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03486158?term=treat+to+target&cond=Inflammatory+Bowel+Diseases&sfpd_s=01%2F01%2F2017&sfpd_e=08%2F20%2F2019&sort=nwst&rank=86
   Google Scholar
• Munkholm P. Are rates of colectomies, resections, mortalities and cancer reduced by home monitoring of IBD patients? 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03038984?term=treat+to+target&cond=Inflammatory+Bowel+Diseases&sfpd_s=01%2F01%2F2017&sfpd_e=08%2F20%2F2019&sort=nwst&draw=2&rank=157
   Google Scholar
• Sheridan J, Coe CA, Doran P, et al. Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772). BMJ Open Gastroenterol. 2018;5(1):e000174.
   PubMed Web of Science ®Google Scholar